High muscle sympathetic nerve activity is associated with left ventricular dysfunction in treated hypertensive

Silvia Beatriz Cavasin de Souza1, Juraci Aparecida Rocha, Marco Antonio Romeu Cuoco

  • 1Heart Institute InCor, Medical School University of Sao Paulo, Sao Paulo, Brazil. sbcavasin.souza@gmail.com

Insights

Hypertension patients with asymptomatic left ventricular diastolic dysfunction (LVDD) show increased muscle sympathetic nerve activity (MSNA), regardless of blood pressure control. This heightened sympathetic activity is similar across different LVDD types.

Area of Science:

  • Cardiology
  • Hypertension Research
  • Autonomic Nervous System Studies

Background:

  • Asymptomatic left ventricular diastolic dysfunction (LVDD) in hypertensive patients is linked to cardiac events.
  • Increased sympathetic activity may contribute to these cardiac outcomes.
  • This study investigates the relationship between LVDD and sympathetic activity in hypertension.

Purpose of the Study:

  • To determine if sympathetic activity is elevated in hypertensive patients with LVDD, independent of blood pressure control.
  • To assess if different classes of LVDD differentially affect sympathetic activity.
  • To explore the role of autonomic dysfunction in hypertensive cardiovascular risk.

Main Methods:

  • 45 hypertensive patients were categorized into normal function, impaired relaxation, and pseudonormal/restrictive LVDD groups based on echo Doppler.
  • A control group of 14 normotensive volunteers was included.
  • Muscle sympathetic nerve activity (MSNA), heart rate, and blood pressure variability, and baroreflex sensitivity were measured.

Main Results:

  • Hypertensive patients with impaired relaxation or pseudonormal/restrictive LVDD exhibited significantly higher MSNA compared to those with normal function and controls.
  • Blood pressure and antihypertensive medication use were comparable across hypertensive LVDD groups.
  • Elevated MSNA was observed independently of blood pressure control.

Conclusions:

  • Asymptomatic LVDD in hypertensive individuals is associated with increased sympathetic nerve activity.
  • This sympathetic hyperactivity is consistent across various patterns of LVDD.
  • LVDD represents a state of autonomic dysregulation in hypertensive patients, potentially increasing cardiovascular risk.
Abstract

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Disorders of the Autonomic Nervous System01:18

Disorders of the Autonomic Nervous System

The autonomic nervous system (ANS) is an intricate network of nerves that controls functions such as the regulation of heart rate, digestion, and blood pressure regulation. When this system malfunctions, it can lead to various disorders that affect multiple bodily functions. One common feature of many autonomic disorders is the involvement of smooth blood vessels, which play a crucial role in regulating blood flow throughout the body.
Raynaud's disease, also known as Raynaud's phenomenon, is a...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...